Abstract: PO1064
Improving the Management of Gout in Patients with CKD or Kidney Transplant: Effect of Online Education
Session Information
- Educational Research
November 04, 2021 | Location: On-Demand, Virtual Only
Abstract Time: 10:00 AM - 12:00 PM
Category: Educational Research
- 800 Educational Research
Authors
- Mehta, Nimish, Medscape LLC, New York, New York, United States
- Maeglin, John, Medscape LLC, New York, New York, United States
- Badal, Karen, Medscape LLC, New York, New York, United States
Background
Gout is a chronic condition with a considerable effect on patient health and quality of life. Hyperuricemia and gout are associated with declining renal function, and recent studies have shown that renal dysfunction and kidney transplant are risk factors for gout. A study was conducted to determine if online, segmented education could improve knowledge, competence, and confidence of nephrologists regarding the management of gout in patients with chronic kidney disease (CKD) or kidney transplant (KT).
Methods
Educational design included a 45-minute video activity with slides, segmented into a series of 5 mini-lectures by different faculty covering various aspects of gout in patients with or without CKD and KT. Educational effectiveness was assessed with a repeated-pairs pre-/post-assessment study design with 3 knowledge questions and 1 confidence question, in which each individual served as his/her own control. A chi-squared test assessed statistical significance at the P <.05 level. The activity launched 9/25/2020, with data collected through 12/4/2020.
Results
The analysis set consisted of responses from nephrologists (n=89) who answered all assessment questions during the study period. Analysis of pre- vs post-intervention responses demonstrated a significant improvement in overall knowledge; average correct responses increased from 52% pre to 76% post education. Specific areas of improvement include:
Treat-to-target strategy with a target of serum UA level < 6 mg/dL in patients taking urate lowering therapy (20% relative improvement, P<.05)
Starting low-dose allopurinol in a patient previously diagnosed with gout and stage 3 CKD, presenting with painful subcutaneous tophi (25% relative improvement, P<.01)
Recommending pegloticase without dose adjustment for the management of refractory gout in patients with stage 4 or 5 CKD (222% relative improvement, P<.001)
Post-education, 48% of nephrologists had a measurable increase in confidence in their ability to manage patients with CKD who may develop gout.
Conclusion
This study demonstrated the success of online, segmented, mini-lectures on improving the evidence-based knowledge, competence, and confidence of nephrologists in appropriately managing gout in patients with CKD or kidney transplant.
Funding
- Commercial Support –